The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported less-than ...

AI business Recursion Pharmaceuticals has narrowed its drug development pipeline, ending or pausing five programmes as it seeks to reduce costs and reprioritise resources following a merger with ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell this week. The stock lost 24% as of market close on Friday. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly.

It continues to draw limited revenue, while its costs are growing notably. For the quarter, Recursion -- which although a clinical-stage company earns some coin from collaboration agreements with ...

What if the patient could have survived beyond those six months? Is it necessary to allow people to terminate their life if they are not in unbearable, physical pain? If your life is your own ...

Recursion Pharmaceuticals (NASDAQ: RXRX) didn't have a fine start to the working week on Monday, at least as far as its stock was concerned. Investors traded out of it following the clinical-stage ...

"Recursion's decade-long investment in AI is driving a decisive, data-led portfolio strategy," said Chris Gibson, Co-Founder and CEO of Recursion. "We are prioritizing high-potential programs to ...

My search has brought me back to Recursion Pharmaceuticals (RXRX), a healthcare company looking to industrialize drug discovery by combining AI, computational power, and their massive-scale datasets.

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Monday reported a loss of $202.5 million in its first quarter. On a per-share basis, the Salt Lake City ...